Debra Kush

4.3k total citations
21 papers, 710 citations indexed

About

Debra Kush is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Debra Kush has authored 21 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Debra Kush's work include Cancer Immunotherapy and Biomarkers (13 papers), Lipoproteins and Cardiovascular Health (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Debra Kush is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lipoproteins and Cardiovascular Health (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Debra Kush collaborates with scholars based in United States, China and Spain. Debra Kush's co-authors include Yi‐Long Wu, Gilberto Lopes, Gilberto de Castro, Yale Mitchel, Tony Mok, Enriqueta Felip, Martin Reck, Takeshi Sawada, Julie R. Brahmer and Shi Rong Han and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The American Journal of Cardiology.

In The Last Decade

Debra Kush

19 papers receiving 691 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debra Kush United States	10	465	353	212	110	102	21	710
Susan Pitman Lowenthal United States	10	256 0.6×	204 0.6×	299 1.4×	195 1.8×	75 0.7×	19	1.1k
Xiting Cao United States	14	255 0.5×	248 0.7×	174 0.8×	110 1.0×	20 0.2×	45	683
Bas Peters Netherlands	15	167 0.4×	149 0.4×	142 0.7×	69 0.6×	30 0.3×	38	464
Felipe Melo Cruz Brazil	13	354 0.8×	279 0.8×	66 0.3×	96 0.9×	38 0.4×	40	674
Òren Smaletz Brazil	12	258 0.6×	440 1.2×	48 0.2×	128 1.2×	43 0.4×	33	732
Joan Minguet Germany	11	154 0.3×	166 0.5×	80 0.4×	61 0.6×	128 1.3×	18	567
Christopher Jakubowski United States	12	203 0.4×	195 0.6×	203 1.0×	79 0.7×	25 0.2×	20	702
E. Mari Italy	11	189 0.4×	344 1.0×	134 0.6×	40 0.4×	63 0.6×	21	572
Robert S. de Jong Netherlands	13	607 1.3×	232 0.7×	119 0.6×	71 0.6×	33 0.3×	21	838

Countries citing papers authored by Debra Kush

Since Specialization

Citations

This map shows the geographic impact of Debra Kush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Kush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Kush more than expected).

Fields of papers citing papers by Debra Kush

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Kush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Kush. The network helps show where Debra Kush may publish in the future.

Co-authorship network of co-authors of Debra Kush

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Kush. A scholar is included among the top collaborators of Debra Kush based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Kush. Debra Kush is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leighl, Natasha B., Luis Paz‐Ares, Delvys Rodríguez‐Abreu, et al.. (2023). 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. Immuno-Oncology Technology. 20. 100537–100537. 8 indexed citations

Peters, Solange, D.H. Lee, Rodryg Ramlau, et al.. (2021). P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy. Journal of Thoracic Oncology. 16(10). S1011–S1012. 3 indexed citations

Wu, Yi‐Long, Li Zhang, Yun Fan, et al.. (2020). Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study. International Journal of Cancer. 148(9). 2313–2320. 77 indexed citations

Leighl, Natasha B., Rina Hui, Delvys Rodríguez‐Abreu, et al.. (2020). Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial. Cancer Research. 80(16_Supplement). CT289–CT289. 5 indexed citations

Wu, Yi‐Long, L. Zhang, Yun Fan, et al.. (2019). MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%. Journal of Thoracic Oncology. 14(10). S290–S291. 6 indexed citations

Nosaki, Kaname, Hideo Saka, Yukio Hosomi, et al.. (2019). Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 135. 188–195. 197 indexed citations

Garon, Edward B., Matthew D. Hellmann, Enric Carcereny, et al.. (2019). Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology. 37(18_suppl). LBA9015–LBA9015. 14 indexed citations

Nosaki, Kaname, Yukio Hosomi, Hideo Saka, et al.. (2019). Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042. Annals of Oncology. 30. ii48–ii48. 7 indexed citations

Lopes, Gilberto, Yi‐Long Wu, Iveta Kudaba, et al.. (2018). Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.. Journal of Clinical Oncology. 36(18_suppl). LBA4–LBA4. 138 indexed citations

10.

Felip, Enriqueta, Matthew D. Hellmann, Rina Hui, et al.. (2018). 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology. 36(15_suppl). 9030–9030. 8 indexed citations

11.

Gangadhar, Tara C., Wen-Jen Hwu, Michael A. Postow, et al.. (2017). Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of Immunotherapy. 40(9). 334–340. 14 indexed citations

12.

Lopes, Gilberto, Yi‐Long Wu, Jin Zhang, et al.. (2016). P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894). Journal of Thoracic Oncology. 11(10). S244–S245. 13 indexed citations

13.

Mok, Tony, Yi‐Long Wu, J. Zhang, et al.. (2016). 195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042. Journal of Thoracic Oncology. 11(4). S142–S142. 4 indexed citations

14.

Kush, Debra, Hyo-Soo Kim, Ji Liu, et al.. (2009). Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. Journal of clinical lipidology. 3(3). 179–186. 3 indexed citations

15.

Kush, Debra, Dayi Hu, Ping Ye, et al.. (2009). Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients. Cardiology. 114(3). 192–198. 16 indexed citations

16.

Farnier, Michel, et al.. (2008). VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. Journal of Lipid Research. 49(12). 2641–2647. 14 indexed citations

17.

Farnier, Michel, Eli M. Roth, Blas Gil Extremera, et al.. (2007). Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. American Heart Journal. 153(2). 335.e1–335.e8. 67 indexed citations

18.

Feldman, Theodore, Michael J. Koren, William Insull, et al.. (2004). Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals. The American Journal of Cardiology. 93(12). 1481–1486. 110 indexed citations

19.

Feldman, Theodore, Michael J. Koren, William Insull, et al.. (2004). M.511 Treatment of high risk patients with ezetimibe plus simvastatin coadministration versus simvastatin alone to attain national cholesterol education program adult treatment panel III low-density lipoprotein cholesterol goals. Atherosclerosis Supplements. 5(1). 118–118. 5 indexed citations

20.

White, HD, Debra Kush, Marcelo Chiara Bertolami, et al.. (1999). Simvastatin and atorvastatin have different effects at high doses on high density lipoprotein cholesterol and apolipoprotein A-I. Atherosclerosis. 144. 30–30.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact